ArticleLasers in medical science2026
Repeated photobiological regulation therapy alleviates inflammation in mice with experimental acute pancreatitis through ROS/NF-κB pathway.
Article in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The prevalence of acute pancreatitis (AP) is increasing, but current treatments remain inadequate. Photobiomodulation (PBM) therapy has demonstrated anti-inflammatory effects under various conditions; however, its role in AP has not been explored. Evaluating this could introduce a noninvasive treatment option for AP. This study aimed to assess PBM’s potential of PBM in reducing cerulein-induced AP inflammation and elucidate the underlying mechanisms. Animal Experiment: Mice were categorized into control, model, and experimental groups. AP was induced with cerulein injections in depilated mice, followed by seven PBM irradiation sessions in the experimental group. Blood samples collected 24 h post-injection were analyzed for TNF-α, IL-6, amylase, and lipase levels. The pancreatic tissue was histologically examined and scored. Cell Experiment: AR42J cells, grouped similarly, were subjected to cerulein exposure and PBM irradiation. An NF-κB inhibitor has been introduced into some groups. Measurements included amylase, NF-κB p65, phosphorylated NF-κB p65, and (Robot Operating System) ROS levels in the supernatant. Animal Experiment: PBM treatment reduced pancreatic tissue edema and serum amylase, lipase, TNF-α, and IL-6 levels. Cell Experiment: ROS levels increased, NF-κB p65 expression decreased, and TNF-α, IL-6, amylase, and lipase in the cell supernatant decreased post-PBM treatment. The addition of the NF-κB inhibitor BAY 11-7082 to the PBM-treated group did not increase ROS levels. PBM therapy shows potential as a noninvasive AP treatment by modulating ROS-mediated NF-κB signaling. Clinical studies are needed to confirm the efficacy and explore the applications of AP treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.